Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
B-Cell Malignancies

About this trial
This is an interventional treatment trial for B-Cell Malignancies focused on measuring non-Hodgkin lymphoma, phosphatidylinositol 3-kinase, myeloproliferative neoplasm
Eligibility Criteria
Inclusion Criteria:
- Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of parsaclisib.
- Currently tolerating treatment in the parent Protocol.
- Currently receiving clinical benefit from treatment with parsaclisib as monotherapy or in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determined by the investigator.
- Has at least stable disease, as determined by the investigator.
- Has demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plans, including PJP prophylaxis, and any other study procedures indicated in this Protocol.
- Willingness to avoid pregnancy or fathering children
- Ability to comprehend and willingness to sign an ICF
Exclusion Criteria:
- Has been permanently discontinued from study treatment in the parent Protocol for any reason.
- Able to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib therapy outside a clinical study.
- Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
- Pregnant or breastfeeding women.
Sites / Locations
- Uab Comprehensive Cancer CenterRecruiting
- University of Alabama At BirminghamRecruiting
- Mayo Clinic Rochester
- University of Arizona Cancer Center-Out Pt.
- City of Hope National Medical Center
- California Cancer Associates For Research and Excellence
- Innovative Clinical Research InstituteRecruiting
- Rocky Mountain Cancer CenterRecruiting
- Rush University Medical Center-Consultants in HematologyRecruiting
- University of Kansas Hospital AuthorityRecruiting
- Rcca Md, Llc
- Massachusetts General HospitalRecruiting
- University of Michigan Cancer CenterRecruiting
- University of Michigan Health SystemRecruiting
- Hattiesburg Clinic HematologyRecruiting
- Saint Luke'S Hospital of Kansas CityRecruiting
- Hca Midwest Health-Research Medical CenterRecruiting
- Comprehensive Cancer Centers of NevadaRecruiting
- Roswell Park Cancer InstituteRecruiting
- Memorial Sloan Kettering Cancer CenterRecruiting
- Duke University Medical Center
- University Hospitals Case Medical CenterRecruiting
- Cleveland Clinic
- The Ohio State University
- Knight Cancer Institute At Oregon Health and Science UniversityRecruiting
- Baylor Scott White Univeristy Medical CenterRecruiting
- University of Washington-Seattle Cancer Care AllianceRecruiting
- Medical University of Vienna
- Cliniques Universitaires Ucl Saint-LucRecruiting
- Universitair Ziekenhuis Gent
- Universitaire Ziekenhuis Leuven - Gasthuisberg
- University Hospital Hradec Kralove
- Univerzita Karlova V Praze 1. Lekarska Fakulta
- University Hospital Kralovkse Vinohrady
- Fakultni Nemocnice V Motole
- The Finsen Centre National HospitalRecruiting
- Sjaellands Universitets Hospital RoskildeRecruiting
- Aarhus University Hospital
- Centre Antoine LacassagneRecruiting
- Ap-Hp Groupe Hospitalier Saint-Louis Lariboisiere Fernand-Widal Site Saint Louis (Paris)
- Hospital Universitaire Pitie-SalpetriereRecruiting
- Centre Hospitalier Universitaire de Toulouse
- Chru Hopitaux de Tours Hospital Bretonneau
- Petz Aladar County Teaching Hospital
- Hadassah Hebrew University Medical Center Ein Karem HadassahRecruiting
- Rabin Medical Center - Beilinson HospitalRecruiting
- Sheba Medical Center
- University of Bologna Institute of Haematology L E A Seragnoli
- Lstituto Di Ematologia Lorenzo Ea.Seragnoli Universita Degli Studi Di Bologna - Policlinico S. Or
- Azienda Ospedaliero-Universitaria Careggi (Aouc)
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori
- Fondazione Irccs Ca Granda Ospedale Maggiore
- Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
- Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
- Universita Di Napoli Federico Ii
- Azienda Ospedaliero Universitaria Maggiore Della Carita Di Novara
- Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
- Azienda Ospedaliero Universitaria PisanaRecruiting
- Ospedale Santa Maria Delle CrociRecruiting
- Ospedale Sant. Eugenio
- Juntendo University Hospital
- National Cancer Center Hospital
- Kansai Medical University Hospital
- Tokai University HospitalRecruiting
- Kobe City Medical Center General HospitalRecruiting
- University Hospital Kyoto Prefectural University of MedicineRecruiting
- Nho Matsumoto Medical CenterRecruiting
- Miyagi Cancer CenterRecruiting
- Jrc Aichi Medical Center Nagoya Daini HospitalRecruiting
- Niigata Cancer Center Hospital
- Osaka Metropolitan University HospitalRecruiting
- Hokuyukai Sapporo Hokuyu HospitalRecruiting
- National Hospital Org. Hokkaido Cancer Center
- Tohoku University HospitalRecruiting
- Tokyo Medical University HospitalRecruiting
- Tenri HospitalRecruiting
- Nippon Medical School HospitalRecruiting
- Yokohama Municipal Citizens HospitalRecruiting
- University of Fukui HospitalRecruiting
- The Catholic University of Korea Seoul St. Mary'S Hospital
- Haukeland University Hospital
- Sp Zoz Szpital Uniwersytecki
- Wwcoit Im. M. Kopernika W Lodzi
- Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu
- Samodzielny Publiczny Szpital Kliniczny Nr 1
- Hospital General Unviersitario de Alicante
- Ico Hospital Germans Trias I PujolRecruiting
- Hospital Del Mar
- Hospital Clinic Barcelona
- Hospital Clinic I ProvincialRecruiting
- Hospital General Universitario Gregorio MaranonRecruiting
- Hospital Universitario Fundacin Jimnez Daz
- Hospital Universitario 12 de Octubre
- Hospital Universitario Hm Sanchinarro
- Hospital Universitario Quironsalud MadridRecruiting
- Hospital Universitario Virgen Del Rocio
- Karolinska University Hospital Solna
- Istanbul Medipol Universitesi Ibagcilar Medipol Mega Universitesi Hastanesi
- Ege University Hospital
- Birmingham Heartlands Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
parsaclisib
parsaclicib + itacitinib
parsaclisib + ruxolitinib
parsaclisib + ibrutinib
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.